Fluocinolone Acetonide 0.19 mg · intravitreal implant
Injections & Implants, Steroid
Approved uses
Diabetic macular edema in patients previously treated with a course of corticosteroids who did not have a clinically significant rise in intraocular pressure
One 0.19 mg implant intravitreally, releasing over about 36 months
Reserved for eyes that have already had a steroid without a pressure spike, which the label makes a precondition
Chronic non-infectious uveitis affecting the posterior segment
One 0.19 mg implant intravitreally
Contraindications
- Active or suspected ocular or periocular infections, including most viral disease of the cornea and conjunctiva, active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases
- Glaucoma with a cup-to-disc ratio greater than 0.8
- Known hypersensitivity to any component of the product
0.19 mg fluocinolone acetonide intravitreal implant in a sterile single-use preloaded applicator with a 25-gauge needle.
Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Corticosteroids are thought to act by inhibition of phospholipase A 2 via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting release of the common precursor, arachidonic acid.
Warnings & Precautions
- Endophthalmitis and retinal detachment: intravitreal injection has been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure and choroidal or retinal detachment. In non-infectious uveitis affecting the posterior segment, hypotony has been seen within 24 hours of injection and resolved within 2 weeks; monitor after injection. Patients may experience temporary blurred vision after injection of the implant.
- Intraocular pressure increase: prolonged corticosteroid use may result in glaucoma with damage to the optic nerve and defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Monitor intraocular pressure routinely during treatment.
- Cataract: use may lead to posterior subcapsular cataract.
- Implant migration: the implant may migrate into the anterior chamber if the posterior capsule is not intact.
- Delayed wound healing: corticosteroids used after cataract surgery may delay healing and increase the incidence of bleb formation.
- Corneal and scleral melting: some ocular diseases and long-term topical corticosteroids can thin the cornea and sclera, and ophthalmic corticosteroids used in eyes with thin corneal or scleral tissue may lead to perforation of the globe.
- Secondary ocular infection: prolonged corticosteroid use may suppress the immune response and raise the risk of secondary ocular infection, and corticosteroids may mask or enhance acute purulent or parasitic eye infections. Reevaluate the patient if signs and symptoms fail to improve after 2 days.
- Viral infection: ocular corticosteroids may prolong and worsen many viral eye infections, including herpes simplex. Use great caution in patients with a history of herpes simplex, with frequent slit lamp microscopy.
- Fungal infection: fungal corneal infection is prone to develop with long-term local corticosteroid use. Suspect it in any persistent corneal ulceration where a corticosteroid has been used or is in use, and take fungal cultures when appropriate.
Common Side Effects
The most common adverse reactions reported are cataract development and increases in intraocular pressure.
Pregnancy: No adequate and well-controlled studies in pregnant women; animal reproduction studies have not been conducted with fluocinolone acetonide. Corticosteroids have been shown to be teratogenic in laboratory animals when given systemically at relatively low dosage levels. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Unknown whether fluocinolone acetonide is present in human milk after intravitreal use. Exercise caution when ILUVIEN is given to a nursing woman.
The safety and effectiveness of ILUVIEN have not been established in pediatric patients.